Evaluation of three commercial methods of susceptibility testing for ceftolozane/tazobactam against carbapenem-resistant Pseudomonas aeruginosa

Abstract

Introduction: Ceftolozane/tazobactam has shown excellent activity against Pseudomonas aeruginosa, but this drug is not always included in commercial panels. The aim of the study was to evaluate the performance of 2 gradient strips (BioMérieux and Liofilchem) and a commercial microdilution panel (Sensititre, EURGNCOL panel) using this combination against carbapenem-resistant P. aeruginosa isolates.

Methods: Three commercial methods were tested with 41 metallo-beta-lactamase-producing and 59 non-carbapenemase-producing P. aeruginosa isolates. Broth microdilution was used as reference.

Results: All carbapenemase-producing isolates and only one non-producing isolate were resistant to this antibiotic. Both essential agreement and bias were outside the acceptance intervals since MIC values were higher than reference values for all three methods. The Kappa index indicated poor or weak agreement. Changes in clinical categories were observed in 3 isolates.

Conclusions: The three methods yielded poor agreement with the reference. Despite the differences in MIC values, fewer than 3% involved category changes.

Keywords: Ceftolozane/tazobactam; Ceftolozano/tazobactam; Gradient strip; Metallo-beta-lactamase; Metalobetalactamasa; Pseudomonas aeruginosa; Sensititre; Sensititre®; Tira de gradiente.